Curia to acquire Integrity Bio
The move allows Curia to expand its biologic formulation and fill-finish capabilities; adding to its drug product aseptic formulation development expertise and drug product manufacturing.
Founded in 2003 as Integrity Biosolution, Integrity Bio’s focus is on hard-to-formulate biologics and fill-finish of unique therapies in preclinical and clinical development. In a typical year, the organization formulates more than 60 large molecules including proteins, antibodies, lipid nanoparticles, peptides and vaccines in liquid and lyophilized form.
In September, the company expanded its facilities to include a second fill-finish line, which more than doubled its manufacturing capacity and complemented the first line with a number of features such as a restricted access barrier system and increased speed.
Located in Thousand Oaks and Camarillo, California, Integrity Bio’s customers range from global Fortune 500 companies to small virtual startups.
Curia – formerly AMRI – says the acquisition will add new capabilities and geographical reach to its operations.
“Curia has decades of experience in managing complexity from R&D through manufacturing,” said Curia Chairman and CEO John Ratliff. “The addition of Integrity Bio is a great fit with our growth strategy and our existing expertise, enhancing our biologics drug product formulation development as well as our fill-finish network. Integrity Bio also adds West Coast coverage to Curia’s East Coast and European capabilities. Together, we can make an even bigger impact on patients’ lives.”
The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.
